Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours

BJU International

Volumn 93, Issue 6, 2004, Pages 845-850

  So, A I ^a   Bowden, M ^a   Gleave, M ^b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Androgen ablation; Androgen independence; Prostate cancer; Shionogi tumour

Indexed keywords

ANDROGEN; CALCIUM CHANNEL BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CASTRATION; CONTROLLED STUDY; DISEASE COURSE; EXPERIMENTAL MODEL; INOCULATION; MALE; MOUSE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; SHIONOGI TUMOR; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR VOLUME;

ANDROGENS; ANIMALS; DISEASE-FREE SURVIVAL; FEMALE; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM RECURRENCE, LOCAL; ORCHIECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 1942445429     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2003.04726.x     Document Type: Article

References (29)

1. Byar DP. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 1126-30
2. Byar DP. VACURG randomised trial of radical prostatectomy for stages I and II prostatic cancer. Veterans Administration Cooperative Urology Research Group. Urology 1981; 17 (Suppl. 4): 7-11
3. Byar DP, Corle. Hormone therapy for prostate cancer, results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988; 7: 165-70
4. Anonymous. Immediate versus deferred treatment for advanced prostatic cancer. Initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997; 79: 235-46
5. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300
6. Messing EM, Manola J, Sarosdy M et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-8
7. See WA, Wirth MP, McLeod DG et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002; 168: 429-35
8. Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor Volume and endocrine and growth factors. Cancer Res 1992; 52: 1598-605
9. Nickerson T, Miyake H, Gleave ME, Pollak M. Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. Cancer Res 1999; 59: 3392-5
10. Schrier RW, Arnold PE, Van Putten VJ, Burke TJ. Cellular calcium in ischemic acute renal failure. Role of calcium entry blockers. Kidney Int 1987; 32: 313-21
11. 2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate 1988; 13: 103-17
12. Martikainen P, Isaacs J. Role of calcium in the programmed death of rat prostatic glandular cells. Prostate 1990; 17: 175-87
13. Isaacs JT, Wake N, Coffey DS, Sandberg AA. Genetic instability coupled to clonal selection as a mechanism for progression in prostatic cancer. Cancer Res 1982; 42: 2353-71
14. Miyake H, Tolcher A, Gleave ME. Antisense Bcl-2 oligodeoxynucleotides delay progression to androgen-independence after castration in the androgen dependent Shionogi tumor model. Cancer Res 1999; 59: 4030-4
15. Miyake H, Rennie P, Nelson C, Gleave ME. Testosterone-repressed prostate message-2 (TRPM-2) is an antiapoptotic gene that confers resistance to androgen ablation in prostate cancer xenograft models. Cancer Res 2000; 60: 170-6
16. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 2275-82
17. Miyake H, Nelson C, Rennie P, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3-kinase pathway. Endocrinology 2000; 141: 2257-65
18. Sato N, Sadar MD, Bruchovsky N et al. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between androgen receptor and AP-1c-Jun in the human prostate cancer cell Line LNCaP. J Bio Chem 1997; 272: 17485-94
19. Craft N, Shostak Y, Carey M, Sawyers C. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Med 1999; 5: 280-5
20. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 1998; 77: 855-61
21. Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 1999; 19: 5143-54
22. Gleave M, Miyake H, Zangemeister-Wittke U, Jansen B. Antisense therapy, current status in prostate cancer and other malignancies. Cancer Metastasis Rev 2002; 21: 79-92
23. Paterson R, Gleave M, Jone E, Zubovits J, Goldenberg SL, Sullivan LD. Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormone therapy. Mol Urol 1999; 3: 277-86
24. Miyake H, Pollak M, Gleave ME. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-1 activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 2000; 60: 3058-64
25. Miyake H, Monia B, Gleave ME. Antisense Bcl-xL and Bcl-2 Oligodeoxynucleotides synergistically enhance taxol chemosensitivity and delay progression to androgen-independence after castration in the androgen dependent Shionogi tumor model. Int J Cancer 2000; 86: 855-62
26. Kiyama S, Morrison K, Zellweger T et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003; 63: 3575-84
27. Henry JM, Isaacs JT. Relationship between tumor size and the curability of metastatic prostatic cancer by surgery alone or in combination with adjuvant chemotherapy. J Urol 1988; 139: 1119-23
28. Isaacs JT. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 1984; 5: 1-17
29. Eng MH, Charles LG, Ross BD. Early castration reduces prostatic carcinogenesis in transgenic mice. Urology 1999; 54: 1112-9